Abstract
Retapamulin activity against 53 isolates obtained from a mupirocin-resistant community-acquired methicillin-resistant Staphylococcus aureus pediatric disease cluster was evaluated using broth microdilution. All strains were susceptible to retapamulin with minimum inhibitory concentrations ≤ 0.5 μg/mL. DNA sequence analysis of rplC and cfr identified one rplC strain variant that did not demonstrate reduced phenotypic susceptibility to retapamulin. These results demonstrate that retapamulin may be a useful alternative therapy for mupirocin-resistant community-acquired methicillin-resistant S. aureus, especially in disease clusters.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 637-638 |
| Number of pages | 2 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 40 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2021 |
Funding
J.L. and this work was supported by a grant from KiDS of New York University Foundation and from the generous donation of Judith and Irwin Kallman. B.S. is supported by the National Institutes of Health grants (R01 AI103268) and NIAID HHS (N272201400019C). A.P. and J.L. have received research grant funding from Aqua Pharmaceuticals. A.J.R. has acted as a consultant for Pfizer and served on an advisory board for Janssen, outside the scope of this work. B.S. has served on an advisory board for MicroGen diagnostics, outside the scope of this work. A donation from the Kallman family supported this work. B.S. is supported by the National Institutes of Health grants R01AI137336-01A1 and R01AI140754-01A1. The other authors have no conflicts of interest to disclose.
Keywords
- children
- cluster
- epidemiology
- methicillin-resistant Staphylococcus aureus
- skin and soft-tissue infection
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Pediatrics, Perinatology, and Child Health
